Johnson Investment Counsel Inc. Reduces Holdings in Humana Inc. (NYSE:HUM)

Johnson Investment Counsel Inc. trimmed its position in shares of Humana Inc. (NYSE:HUM) by 1.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,274 shares of the insurance provider’s stock after selling 48 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Humana were worth $831,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Transcend Capital Advisors LLC boosted its stake in shares of Humana by 399.7% during the fourth quarter. Transcend Capital Advisors LLC now owns 3,643 shares of the insurance provider’s stock valued at $924,000 after purchasing an additional 2,914 shares during the period. FNY Investment Advisers LLC boosted its stake in shares of Humana by 6,647.5% during the fourth quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider’s stock valued at $6,916,000 after purchasing an additional 26,856 shares during the period. Retirement Systems of Alabama boosted its stake in shares of Humana by 735.9% during the fourth quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock valued at $55,563,000 after purchasing an additional 192,801 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Humana by 7.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 964,926 shares of the insurance provider’s stock valued at $244,811,000 after purchasing an additional 65,735 shares during the period. Finally, PDT Partners LLC boosted its stake in shares of Humana by 190.0% during the third quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider’s stock valued at $1,286,000 after purchasing an additional 2,660 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.32% of the company’s stock.

Humana Stock Performance

HUM opened at $249.32 on Thursday. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The company has a market cap of $30.08 billion, a P/E ratio of 25.06, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The firm’s 50-day moving average price is $271.59 and its 200-day moving average price is $281.42.

Humana (NYSE:HUM) last posted its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, equities analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.42%. Humana’s dividend payout ratio (DPR) is currently 35.58%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Barclays boosted their target price on shares of Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research note on Thursday, February 13th. Piper Sandler upped their price objective on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $283.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Morgan Stanley lowered their price objective on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 12th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research note on Tuesday, February 18th. Twenty research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.